James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL
2014 ASH Annual MeetingRelated Videos
Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survi...
Richard M. Stone, MD, on the SAL-SORAML Trial
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6,
Linda J. Burns, MD, on CAR T-Cell Therapy in ALL
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380,
Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combin...
Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379,
